Abion

Abion develops experimental cancer drugs and antiviral therapies, aiming to match treatments to individual patients based on their specific biological markers, a precision-medicine approach known as companion diagnostics.

Its drug candidates target conditions including non-small-cell lung cancer and a range of solid tumors, and are intended for use in clinical and hospital settings. Listed on KOSDAQ, Korea's tech-focused stock exchange, Abion's pipeline centers on biomarker-driven research to identify which patients are most likely to respond to a given therapy.